News Sentiment

CHM sentiment intelligence

Chimeric Therapeutics Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 21 relevant articles
Exchange ASX Australia
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.05 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

95/100 classification confidence.

Company focus 21

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-10.3% over one week, -30.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Chimeric Therapeutics (ASX:CHM) posts 40% tumour shrinkage at top dose in CAR-T trial

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 95/100 classification
One-week reaction -10.3% Price reacting lower
Trend fit Trend inactive -30.7% over four weeks
Fair value -95.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 1
Neutral 20
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 21
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Kalkine 11
Stocks Down Under 3
The Globe and Mail 2
Market source 1
Stockhead 1
Sharecafe 1
BiotechDispatch 1
TradingView 1

Event Lens

What the news is about

Classified themes
Market update 21

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-21 of 21